Quality Assurance Scheme Development Group
The Quality Assurance Scheme Development Group (QASDG) will develop the European Quality Assurance Scheme for Breast Cancer Services (the European QA scheme) to set common quality and safety requirements for person-centred breast cancer services in Europe. The scheme will cover all the processes of breast cancer care (screening, diagnosis, treatment, rehabilitation & supportive care, follow-up & survivorship care and palliative care) and will be underpinned by the accreditation legal framework and evidence from guidelines.
The QASDG discusses and selects the requirements within virtual working environments and in meetings organised every three months.
The members are also invited to contribute to the other ECIBC objectives, the Digital Mammography Training Template and the European Guidelines Platform covering all processes of care (from screening to end-of-life care).
The QASDG is supported by the external contractors EA- European Co-operation for Accreditation for the accreditation legal framework and for the coordination of national accreditation bodies, by CCIb –Iberoamerican Cochrane Centre for literature review and by IQ healthcare to develop indicators.
Members and external experts
Univ.-Prof. Dr. med Sara Brucker is Deputy Executive Director of the Department of Women's Health and Medical Director of the Research Centre for Women's Health at Tübingen University.
In 2006 she became Senior Attending and Chair of the Institute of Women's Health at Tübingen University Women's Hospital. Since 2009 she is Chair of the Centre of Rare Genital Malformations at the Centre of Rare Diseases (ZSE).
2008 she was rewarded with the prestigious Gunter-Bastert-Innovation-Prize of the DGG (German Society for Gynecology and Obstetrics) for the "Implementation of the Certification Process of Breast Cancer Centres and their Digital Documentation". She is congress president of the Annual Meeting of the DGGG in 2016 and the Editor of "Senologie" journal and member of the Se-Guideline Working Group for Diagnostic Therapy and follow-up in breast cancer.
Major fields of research:
Quality assurance in breast cancer.
Guideline development and implementation.
Basic research in breast cancer (new prediction and prognosis factors, minimal residual disease)